Roberto Ceratti Manfro

Three-Year Outcomes From BENEFIT-EXT: A Phase III Study of Belatacept Versus Cyclosporine in Recipients of Extended Criteria Donor Kidneys

José Osmar Medina Pestana, J.M. Grinyó, Yves Vanrenterghem et al. · American Journal of Transplantation · 2012 · 259 citations · Full text

Recurrence of FSGS after Kidney Transplantation in Adults

Audrey Uffing, María José Pérez‐Sáez, Marilda Mazzali et al. · Clinical Journal of the American Society of Nephrology · 2020 · 173 citations · Full text

Effect of Food on the Pharmacokinetics of Cyclosporine in Healthy Subjects Following Oral and Intravenous Administration

Suneel K. Gupta, Roberto Ceratti Manfro, Stephen J. Tomlanovich et al. · The Journal of Clinical Pharmacology · 1990 · 120 citations

Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial

Josep M. Grinyó, María del Carmen Rial, Josefina Alberú et al. · American Journal of Kidney Diseases · 2016 · 106 citations · Full text

Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial

Lionel Rostaing, Suphamai Bunnapradist, Josep M. Grinyó et al. · American Journal of Kidney Diseases · 2015 · 96 citations · Full text